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Abstract
Background: Hepatitis C virus (HCV) infection is a major public health challenge worldwide. Implementing policies
to cope with this challenge requires commitment from all stakeholders at various levels, and all necessary resources
should be mobilised. Support for various HCV-related stakeholders can reduce the challenges and obstacles that
can be encountered during the programme implementation. The present study aims to identify all stakeholders
involved with HCV-related policy-making in Iran at different steps (policy development, implementation and
evaluation) and to characterise them in terms of interest, position, power and influence, in order to provide
valuable information for appropriate decision-making and design. The present study can also serve as a case study
for healthcare systems in other countries.
Method: An approach based on social network analysis was utilised. Data collected included relevant document
searches and in-depth interviews to a sample of 18 key informants.
Results: Various stakeholders were found to be involved with HCV-related policies in Iran. The extent of their
participation and support in policy-making varied. Specifically, international agencies had a high interest for HCV-
related policy-making, whereas media and members of the private sector were characterised by a medium interest
and governmental and non-governmental bodies by a highly variable interest, ranging from low to high,
depending on the specific organism. Moreover, media and members of the private sector, non-governmental
institutions and international agencies were rated low in terms of position, whereas governmental actors were
rated low to high. Media were rated medium in terms of power, whereas international agencies and members of
the private sector were respectively rated low to medium and low. Non-governmental actors were rated low, whilst
governmental bodies were rated low to high. Finally, media, members of the private sector and international
agencies were rated medium in terms of influence, whereas non-governmental and governmental actors were
respectively rated low to medium and low to high.
Conclusion: Policy-making involves trust, negotiation and integration of the different views of all stakeholders.
Social network analysis was critical for identifying stakeholders and showing that, in Iran, involvement in HCV-
related policy-making is generally low. This information is of practical implication for policy- and decision-makers
regarding the adoption of more favourable and effective strategies.
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Background
Hepatitis C virus (HCV) infection is a major public health
challenge worldwide [1]. Chronic HCV infection can po-
tentially lead to complications such as decompensated cir-
rhosis, liver failure and hepatocellular carcinoma [2].
Prevention, control, diagnosis and treatment are essential
and should receive special attention from health decision-
and policy-makers [3]. It is estimated that, globally, ap-
proximately 71 million people are affected by chronic
HCV, and approximately 399,000 people die each year due
to cirrhosis and hepatocellular carcinoma [4]. WHO re-
ported that the highest prevalence of HCV was found in
the Eastern Mediterranean Regional Organization
(EMRO) region, with a rate of approximately 2.3%, whilst
Europe has a prevalence of approximately 1.5% [5]. Health
policy- and decision-makers are working to implement
HCV-related programmes, mitigating the burden gener-
ated by the infection and providing effective treatment to
patients [6]. Despite the lack of funding, efforts are made
to reduce the health-related costs of the illness [7] and to
provide a variety of financially sustainable programmes in
order to reduce mortality and transmission of disease to
the general population [8].
Implementing different policies to properly cope with
HCV requires commitment from all stakeholders at the
international, national and regional levels, with all facil-
ities and resources that should be effectively mobilised
to implement these policies. Support for various
HCV-related stakeholders can reduce problems and ob-
stacles that can be encountered during the implementa-
tion of the programme [9]. Support can include
participation in policy-making, advising and suggesting
appropriate policies, providing adequate funding needed
to implement policies, discussing and resolving potential
disagreements over policy implementation, and engaging
with policy- and decision-makers to counteract the
spreading of HCV [10].
Healthcare problems are complex, nonlinear and
multi-factorial, and the various stakeholders involved in
the process of policy-making may have a different im-
pact on them [11]. Stakeholders include all the individ-
uals, groups and organisations that can influence a given
health-related issue. The diversity of views among stake-
holders can affect the process of policy implementation
[12]. Understanding and characterising stakeholders can
raise awareness of the various dimensions underlying the
decision-making process and potentially improve it.
Stakeholder analysis is a systematic process that consists
of identifying and characterising stakeholders in terms of
interests, power and relationships to a given
health-related policy [12].
Concerning HCV in Iran [13], some studies have been
conducted on the prevalence of this infection in different
groups. For example, the prevalence rate is 0.6% in the
general population [14], 0.5% in blood donors [15], 41.3%
in injection drug users [16], 19% in thalassemia patients
[17], 28% in prisoners [18], 11% in haemodialysis patients
[19], and 2.4% in street children [20]. Based on these epi-
demiological findings, health policy- and decision-makers
are implementing various ad hoc policies to cope with the
disease [21]. However, as previously mentioned, the pres-
ence of different stakeholders with different interests and
expectations towards health-related policies is one of the
challenges to the implementation of various programmes
[22], in that it is difficult to meet all expectations. The sys-
tematic identification and study of the stakeholders in-
volved with a given policy through social network analysis
(SNA) can enable the development of a constructive dia-
logue and of interactions based on their position, interests
and impact on that policy [23]. Understanding the actors
and their interests will make it possible to know how to
develop and implement policies to counteract the spread-
ing of HCV. Stakeholders, in relation to a given
health-related policy, are actors that can have a direct or
indirect effect/influence and may increase or weaken the
authority and effects of that policy [24].
The Ministry of Health and Medical Education
(MoHME) is the main sponsor of health in Iran. The gov-
ernment, according to the different needs of the ministries
and their programmes, provides the necessary budget.
The parliament, according to the representatives of the
delegates, ultimately approves the budget and adopts mea-
sures to implement it [25]. The MoHME allocates ad-
equate financial resources for each programme and runs
them through its medical universities (MUs) in all prov-
inces. For other programmes and policies, other ministries
can support the MoHME [26]. More specifically, the Na-
tional Hepatitis Committee based at the Centres for Dis-
ease Control and Prevention, focuses on major
HCV-related programmes in order to implement them.
HCV-related policies are run through the Secretariat of
the Supreme Council for Health and Food Security, in col-
laboration with other ministries if needed. Implementation
of HCV-related plans is under the responsibility of the
MoHME, health authorities and organisms, and other or-
ganisations that independently monitor the various pro-
cesses through different quality indicators [27].
The present investigation aims to analyse the roles and
characteristics of all stakeholders involved in HCV-related
policies in Iran in order to provide valuable information
for designing proper plans and making appropriate deci-
sions about HCV-related policies. It may also serve as a
case study for healthcare systems in other countries.
Methods
Stakeholder identification and analysis
Based on our aim, in order to examine the various di-
mensions and effects that stakeholders can have on
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HCV-related policies in Iran, the suggestions and the
theoretical framework adopted by the World Bank [28]
and by Varvasovsky et al. [24] were deemed appropriate
and chosen for our study. As such, stakeholders were
analysed and characterised based on four items, namely
interest, position, power and influence.
Data were collected in two phases. Firstly, identifica-
tion of the stakeholders (through interviews and docu-
ments) and, secondly, assessment of the view of
participants towards stakeholder’s roles (through expert
opinions). In-depth interviews were conducted with key
informants involved in HCV-related programmes and
policies. The full list of participants is shown in Table 1.
The main question framed was, ‘who are the main
HCV-related actors (such as organisations or institu-
tions) involved with the processes of policy-making in
Iran?’ Within this step, HCV-related policy documents
(including documents prepared and implemented by the
government, the MoHME, the parliament, related orga-
nisations, media, health insurance, as well as WHO and
non-governmental organisation (NGO) reports, news
sites and scholarly literature on HCV policy-making)
were also consulted and thoroughly inspected. The inter-
viewees were selected through purposive sampling and
snowballing. Participants who had experience and know-
ledge about HCV-related programmes were interviewed
and asked to introduce further actors involved with
HCV-related policies. The interviews continued until a
new actor was added and until data saturation was
achieved. At the beginning of the interview, a consent
form was given to the interviewees and they were in-
formed about the aims of the present study. Interviewed
participants included policy- and decision-makers, med-
ical specialists, physicians, health department adminis-
trators, university professors, medical academicians,
journalists, nurses, hospital and insurance managers,
and pharmacists. Interviews were conducted by two au-
thors (MB and HAG). Based on the views of the partici-
pants, data were analysed by three authors (MB, HAG
and AR). Subsequently, after collecting data, a list of all
actors and stakeholders was obtained based on both in-
terviews and document searches. All documents related
to HCV in the field of prevention and treatment, of any
type (meeting abstracts and conference proceedings,
laws, regulations, rules, reports, articles, books, news
and speeches) were evaluated (Table 2).
An ad hoc questionnaire was created in which stake-
holders were rated in terms of interest, position, power
and influence on HCV-related programmes and policies.
Specifically, interest was defined as the degree of in-
volvement with a given HCV-related policy; position was
defined as the number of connections or interactions
with other actors involved in the process of HCV-related
policy-making; power was defined as the degree or ex-
tent to which the stakeholder was deemed likely to affect
and modify a certain HCV-related policy; and influence
was defined as the amount of potential benefits (includ-
ing money, facilities, mobilised resources and know-
ledge) relevant to HCV-related decisions. For each item
of the questionnaire (interest, position, power and influ-
ence) a five-point answer (low, low-medium, medium,
medium-high, and high) was possible.
During the second phase, the list containing all the
names of stakeholders/actors involved with HCV-related
programmes and policies in Iran and the questionnaire
were sent by email to the interviewees. Finally, the aver-
age score of the participants for each stakeholder was
computed.
Social network analysis (SNA)
A network characterised by properly balanced interactions
among different stakeholders can lead to the development
and implementation of adequate health-related policies
[29]. Analysing this network can be a way to understand
the structure of the process of policy-making and the rela-
tionships and interactions among the different stake-
holders [30] in terms of relevance of each actor [31].









State Prisons and Security and Corrective Measures Organisation 1
Pharmaceutical companies managers 1
University professors 2
Non-governmental organisations 2
Iranian Red Crescent 1
Social media 1
Table 2 List of HCV-related documents consulted in the
present study
Type of document Number
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SNA is a sophisticated computational approach that
shows the structure of the process of communication,
relationships and interactions among the various stake-
holders [32]. SNA shows also which parts of the network
need more attention and dialogue, in order to ensure a
proper healthcare policy-making process [33] and to
achieve effective cooperation between different stake-
holders [34]. SNA enables computing of network met-
rics, including degree, closeness, betweenness and
eigenvector centralities.
Specifically, degree centrality is the number of direct
relationships (links/edges connecting neighbouring
nodes) that a stakeholder has [35]. Closeness centrality
(or simply closeness) is the reciprocal of the sum of the
length of the shortest interactions (paths, links or edges)
between a stakeholder (node) and all the other actors
(nodes) [36]. Betweenness centrality is based on the
shortest paths, wherein a stakeholder can, indeed, reach
other stakeholders (neighbouring nodes) through differ-
ent paths, but only the shortest one is computed [37].
Eigenvector centrality is a proxy of the influence of a
stakeholder and its importance in terms of connections
with high-scoring (‘central’) nodes [38]. To carry out
SNA, average scores were used based on the views of
the participants, as well as the association of each organ-
isation/institution with all the other organisations. Data




The length of each interview varied between 10 and 15min.
After interviewing a sample of 18 participants and reviewing
related and pertinent documents, 29 HCV-related stake-
holders in Iran were identified, as reported in Table 3.
Specifically, identified stakeholders included the Iran-
ian Parliament (Majlis, directly elected with the vote of
the people, involved in legislation, approval and moni-
toring of funds, and enforcement of the laws), the Judi-
cial system, the State Prisons and Security and
Corrective Measures Organisation (SPSCMO), the
MoHME, the Imam Khomeini Relief Foundation (IKRF,
which sponsors and provides funding to poor people in
the community), the Law Enforcement Force (LEF), gov-
ernmental pharmaceutical companies (GPCs, involved in
the preparation and production of medicines with the
support of government funds), governmental insurances
(GIs), MUs, the Iranian Blood Transfusion Organisation,
the Ministry of Education (MoE), the State Welfare Or-
ganisation (SWO, involved in the improvement of social
welfare, supporting unemployed people and developing ad
hoc training programmes), the military forces, the Minis-
try of Sport and Youth (MoSY), the Ministry of Science,
Research and Technology (MoSRT), the Iran Drug Control
Headquarters (IDCH), the Municipalities, NGOs, scientific
centres, the elites, the Iranian Red Crescent (IRC, which
provides medicines and support to poor and ill people), the
clerics, the Islamic Republic of Iran Broadcasting (IRIB,
state-directed), news websites (society-directed), social
media (society-directed), private pharmaceutical companies
(PPCs, involved in the preparation and production of medi-
cines with the financial support of the private sector), pri-
vate insurances (PIs), WHO, and EMRO.
Stakeholders were classified into five groups, namely
(1) governmental, (2) NGOs, (3) media, (4) members of
the private sector, and (5) international agencies. More
in detail, 16 stakeholders (55.17%) related to
HCV-policies and programmes in Iran were governmen-
tal agencies. Six stakeholders (20.68%) were NGOs.
Three stakeholders (10.34%) were political and media
groups, whilst two stakeholders (1.73%) were members
of the private sector and international agencies.
The identified stakeholders were involved in differ-
ent steps of the process of HCV-related
policy-making. For instance, the MoHME was in-
volved in policy development, implementation and
evaluation, whereas SPSCMO in implementation,
MUs in policy implementation and evaluation, and
IDCH in policy development. Estimated interest,
position, power and influence of key stakeholders in-
volved with HCV policy-making in Iran are shown
in Table 4.




Parliament (Majlis), Judicial system, State Prisons and Security and Corrective Measures Organisation, Ministry of
Health and Medical Education, Imam Khomeini Relief Foundation, Law Enforcement Force, Government
pharmaceutical companies, Government insurances, Medical Universities, Iranian Blood Transfusion Organisation,
Ministry of Education, State Welfare Organisation, Military forces, Ministry of Sport and Youth, Ministry of Science,
Research and Technology, Iran Drug Control Headquarters
NGOs (6 stakeholders) Municipalities, non-governmental organisations, Scientific centres, Elites, Iranian Red Crescent, Clerics
Media (3 stakeholders) Islamic Republic of Iran Broadcasting, news websites, social media
Private sector (2 stakeholders) Private pharmaceutical companies, private insurances
International agencies (2
stakeholders)
WHO, Eastern Mediterranean Regional Organization
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Interest analysis
Among the stakeholders identified, the MoHME and the
MUs (the main healthcare providers in Iran), the IBTO
(the major provider of blood transfusion and blood do-
nation), WHO and EMRO had the highest interest level
towards HCV-related policies in Iran. Moreover, accord-
ing to the scores given by the participants, the SPSCMO
and PPCs had a medium-high interest for HCV-related
policies. Prisoners, as one of the most high-risk groups
for HCV, have led the SPSCMO authorities to take an
interest in harm reduction programmes for prisoners.
PPCs have become interested in developing anti-HCV
drugs in recent years. Elites, GIs, GPCs, IDCH, news
websites, PIs, scientific centres and social media had
medium interest for the process of HCV-related
policy-making. Stakeholders like the IKRF, the IRC, the
IRIB, the Judicial system, the LEF, NGOs, the Iranian
Parliament, and SWO were found to have a low–
medium interest for HCV-related policy-making. Other
stakeholders, such as clerics, municipalities, military
forces, the MoE, the MoSRT, and the MoSY, had a low
interest towards HCV-related policies. Thus, inter-
national agencies had a high interest for HCV-related
policy-making, whereas media and members of the pri-
vate sector were characterised by a medium interest and
governmental bodies and NGOs by a highly variable
interest, ranging from low to high, depending on the
specific organism.
Position analysis
The MoHME has been recognised as the most import-
ant stakeholder in terms of position, having much
Table 4 Stakeholders involved with the process of HCV-related policy-making in Iran rated according to four items (interest,
position, power and influence)
Stakeholders Interest Position Power Influence
Clerics Low Low Low Medium
Eastern Mediterranean Regional Organization High Low Low Low-medium
Elites Medium Low-medium Low High
Government insurances Medium Medium-high High High
Government pharmaceutical companies Medium Medium-high Medium High
Imam Khomeini Relief Foundation Low-medium Low Low Medium
Iran Drug Control Headquarters Medium Low Medium-high Medium
Iranian Blood Transfusion Organisation High High Medium High
Iranian Red Crescent Low-medium Low Low Medium
Islamic Republic of Iran Broadcasting Low-medium Low Low-medium High
Judicial system Low-medium Low Medium-high Medium
Law Enforcement Force Low-medium Low Low Low-medium
Medical Universities High High Medium-high High
Military forces Low Low Low Medium
Ministry of Education Low Low Low Medium
Ministry of Health and Medical Education High High High High
Ministry of Science, Research and Technology Low Low Low Low
Ministry of Sport and Youth Low Low Low Medium
Municipalities Low Low-medium Low Low
News websites Medium Low Medium Medium
Non-governmental organisations Low-medium Low Low Medium
Parliament Low-medium Low High High
Private insurances Medium Low Low Medium-high
Private pharmaceutical companies Medium-high Low Low Medium
Scientific centres Medium Low Low Medium-high
Social media Medium Medium Medium Medium
State Prisons and Security and Corrective Measures Organisation Medium-high High High Medium-high
State Welfare Organisation Low-medium Medium Medium High
WHO High Low Medium Medium
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support for all its activities aimed at preventing, control-
ling and treating the disease. Additionally, stakeholders
such as the IBTO, MUs and the SPSCMO were found to
rank high in terms of position. Furthermore, GIs and
GPCs were rated medium–high; they have, indeed, in-
creased their support for reducing the costs and helping
patients to adhere to treatment. Social media and SWO
were rated medium, whereas municipalities and elites
were rated low–medium in terms of position. PPCs also
play a relatively important role in patient treatment pro-
grammes, despite being rated low together with clerics,
the EMRO, the IKRF, the IDCH, the IRC, the IRIB, the
LEF, the Judicial system, the military forces, the MoE,
the MoSRT, the MoSY, news websites, NGOs, the Iran-
ian Parliament, PIs, scientific centres, and WHO. Sum-
marising, media as well as members of the private
sector, NGOs and international agencies were rated low
in terms of position, were governmental actors were
rated low to high.
Power analysis
Participants rated the Parliament, the MoHME, GIs, and
the SPSCMO as the most important HCV-related pol-
icy- and decision-makers in terms of power. In recent
years, for instance, the SPSCMO has taken effective
steps to control the disease through screening activities
for prisoners in collaboration with the MoHME and the
Judicial system. The latter, together with IDCH and the
MUs, has a medium–high power. Actors like GPCs, the
IBTO, news websites, social media, SWO, and WHO
were found to have medium power, whereas the IRIB
was rated low–medium. In general, most stakeholders,
including clerics, the EMRO, elites, the IKRF, the IRC,
LEF, military forces, the MoE, the MoSRT, the MoSY,
municipalities, NGOs, PIs, PPCs, and scientific centres,
were rated low in terms of power. Many organisations,
despite having the institutional tasks and duties of con-
trolling the spread of HCV, do not use their power to in-
fluence HCV-related plans and programmes in Iran. In
summary, media were rated medium in terms of power,
whereas international agencies and members of the pri-
vate sector were respectively rated low to medium and
low. Non-governmental actors were generally rated low,
whilst governmental bodies were rated low to high.
Influence analysis
The MoHME, the Iranian Parliament, GPPs, GIs, MUs,
the SWO, the IRIB, and the IBTO have a great influence
on the policy of HCV-related screening and treatment
programmes, as well as on the economic and financial
plans. In general, the community elites have an import-
ant role to play in influencing policies, and they can pro-
vide Iran with more effective programmes by
communicating effectively with policy- and
decision-makers and expressing their views. PIs, scien-
tific centres, and the SPSCMO were rated medium–high
whereas clerics, the IKRF, the IDCH, the IRC, the Judi-
cial system, the military forces, the MoE, the MoSY,
news websites, NGOs, PPCs, social media and WHO
were rated medium. EMRO and LEF were considered to
have a low–medium influence, whereas the remainder
(the MoSRT and municipalities) were judged to have a
low influence. Summarising, media, members of the pri-
vate sectors and international agencies were rated
medium in terms of influence, whereas
non-governmental and governmental actors were re-
spectively rated low to medium and low to high.
Social network analysis (SNA)
The computed network metrics, including degree, close-
ness, betweenness and eigenvector centralities, are re-
ported in Tables 5 and 6. Based on the SNA-related
items, the MoHME had the highest rank for
HCV-related policies in Iran, being the authority which
writes, enforces and funds healthcare policies. Based on
these findings, stakeholders like social media, news web-
sites and the IRIB are the most centralised after the
MoHME and Parliament. Network and node-level met-
rics are shown in Tables 5 and 6. Network maps based
on interest, position, power and influence of the differ-
ent stakeholders involved with HCV policy-making in
Iran are respectively shown in Figs. 1, 2, 3 and 4.
Discussion
The findings of this study showed that the identified
stakeholders have a different spectrum of interest, pos-
ition, power and influence on HCV-related policies in
Iran. Identifying these stakeholders is an important fac-
tor for succeeding in developing and implementing ef-
fective interventions and mobilising all necessary
resources and facilities [39, 40]. Regarding HCV-related
policy in Iran, the identified stakeholders directly and in-
directly influence the formulation and implementation
of policies. According to participant’s viewpoints, the
MoHME is the most important stakeholder identified.
Disagreements and different standpoints concerning
the development and implementation of healthcare pol-
icies can be a challenge [41], despite negotiations being
able to mitigate such contrasts and contribute to finding
an optimal compromise [42]. In the case of HCV-related
policies in Iran, a lack of cooperation has hindered a
proper implementation of the plans [10]. Based on the
ranks and metrics properties of the stakeholders, one of
the noticeable findings of the present investigation is
that, despite the fact that HCV has been properly identi-
fied as a challenge for Iran’s health sector, many stake-
holders believe that they could not do much. Indeed,
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many stakeholders tend to consider the disease merely
as a priority of the MoHME.
The identified stakeholders showed different degrees
of interest towards HCV-related policy. Their differing
motivation can explain this [43]; for example, interest by
the IKRF and SWO was found to be low despite being
important organisations that help poor people. On the
other hand, stakeholders rated high for position can have
a high impact on other stakeholders. The political, eco-
nomic, social and cultural status of each stakeholder in-
deed plays an important role in the process of
policy-making. The power of stakeholders is one of the
main factors and components of the development and
implementation of health-related policies [44]. However,
Table 5 Network metrics, including degree, closeness, betweenness and eigenvector centralities, computed for the different









Ministry of Health and Medical Education 29 1 74.85 1.00
Parliament 25 0.90 26.18 0.97
Social media 25 0.90 26.18 0.97
News websites 25 0.90 26.18 0.97
Islamic Republic of Iran Broadcasting 18 0.73 7.44 0.78
Law Enforcement Force 17 0.71 9.01 0.73
Judicial system 16 0.70 6.50 0.70
Clerics 15 0.68 4.69 0.67
Elites 14 0.66 2.64 0.66
Imam Khomeini Relief Foundation 14 0.66 9.58 0.59
Municipalities 13 0.65 2.49 0.61
Government insurances 13 0.65 6.08 0.55
Medical Universities 13 0.65 5.41 0.58
Iran Drug Control Headquarters 13 0.65 1.69 0.63
State Prisons and Security and Corrective Measures
Organisation
12 0.63 1.23 0.59
State Welfare Organisation 12 0.63 2.43 0.55
Scientific centres 11 0.62 1.60 0.53
Non-governmental organisations 11 0.62 1.11 0.54
Ministry of Science, Research and Technology 9 0.59 0.74 0.43
Iranian Blood Transfusion Organisation 9 0.59 1.00 0.41
Military forces 8 0.58 0.21 0.41
Iranian Red Crescent 8 0.58 0.56 0.40
Government pharmaceutical companies 8 0.58 1.43 0.38
Ministry of Education 8 0.58 0.30 0.42
Ministry of Sport and Youth 7 0.57 0.09 0.38
WHO 6 0.56 2.00 0.30
Private insurances 4 0.53 0.14 0.16
Private pharmaceutical companies 4 0.53 0.12 0.19
Eastern Mediterranean Regional Organization 2 0.51 0.00 0.08






Average clustering coefficient 0.746
Number of triangles 564
Diameter 2
Average path length 1.546
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regarding HCV-related policy in Iran, participation and
involvement in political discussions for policy-making
are generally low, and this is a challenge that can affect
policy implementation by causing delays or resulting in
failures.
Experts believe that, in order to improve policy and
implementation, both top-down and bottom-up ap-
proaches should be used to allow continuous
implementation of policies [45]. Specifically with regards
to HCV policy in Iran, most decisions are taken by the
MoHME, with a low participation of other stakeholders
and a lack of appropriate dialogue with the bottom-up
beneficiaries. Through a more intense political dialogue,
these weaknesses could be somewhat reduced. Moreover,
due to the limited financial resources and economic dif-
ficulties caused by international sanctions in Iran, not all
Fig. 1 Network map based on the interest of different stakeholders involved with HCV policy-making in Iran
Fig. 2 Network map based on the position of different stakeholders involved with HCV policy-making in Iran
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the necessary financial resources for the treatment of pa-
tients are provided to every patient. Although some new
financial resources have been planned since the imple-
mentation of the Health Transformation Plan in Iran,
these resources have not been fully allocated [46].
Stakeholders can influence policies based on their own
characteristics and their effects can be positive or nega-
tive [47]. Regarding the prevention dimension, IRIB, so-
cial media, news websites and clerics have a great
influence on society. Unfortunately, despite this high
Fig. 3 Network map based on power of different stakeholders involved with HCV policy-making in Iran
Fig. 4 Network map based on influence of different stakeholders involved with HCV policy-making in Iran
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potential, because of certain cultural problems associated
with HCV, such as stigma, they have not been successful
in fulfilling the mission of raising awareness. However,
in recent years, the MoHME has tried to reduce
HCV-related stigma, and stakeholders are working with
the MoHME to raise awareness among the general
population.
The findings of the present study showed that network
density was generally low. Collaboration and interactions
among all involved stakeholders at all levels should be
extensively adopted to address important issues such as
HCV. They should have a comprehensive understanding
of the magnitude and impact of their collaboration.
Cultural factors and community views can affect
health policies [48, 49]. In the Iranian society, stigma is
still high and, therefore, SNA findings showed that those
who are responsible for spreading information and rais-
ing awareness should have a more active participation
and a greater role in preventive policies; the centrality of
stakeholders such as social media, news websites and the
IRIB emphasised this issue.
Finally, the findings of this study showed that the on-
going dialogue between stakeholders favours more sensi-
tivity and empowerment, potentially resulting in an
integration of some programmes. Consultation with all
involved stakeholders can help in the design and imple-
mentation of adequate policies.
Conclusion
The findings of this study showed that there are many
stakeholders involved with HCV-related policy in Iran.
The extent of their participation and support in the
process of policy-making is different and variable. In
general, involvement in HCV-related policy-making is
low. This information has practical implications for pol-
icy- and decision-makers, helping them to adopt more
favourable and effective strategies. HCV-related
policy-making and decision processes should not be
handled by the MoHME alone, but should receive sup-
port and advocacy from all involved stakeholders. This is
essential for succeeding in the ambitious goal of man-
aging and controlling this disease. Proper policy-making
involves trust, ongoing negotiations, integration and im-
plementation of the different views of all involved stake-
holders. In the present investigation, SNA was a critical
point for identifying stakeholders as well as gaps and
weaknesses so that policy- and decision-makers can have
a more comprehensive understanding of health issues
and processes and make better-informed decisions.
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